Baseline characteristics and survival data for patients with and without an iAMP21
| Variable* . | Patients with iAMP21 . | Patients without iAMP21 . | P . |
|---|---|---|---|
| Total, no. (%) | 28 (100) | 1602 (100) | |
| Sex, no. (%) | |||
| Female | 13 (46) | 693 (43) | .737 |
| Male | 15 (54) | 909 (57) | |
| Age, no. (%) | |||
| 1-4 y | 0 (0) | 812 (51) | < .001 |
| 5-9 y | 17 (61) | 458 (29) | |
| 10+ y | 11 (39) | 332 (21) | |
| Ethnicity, no. (%) | |||
| White | 1378 (87) | 23 (85) | .720 |
| Nonwhite | 197 (13) | 4 (15) | |
| Down syndrome, no. (%) | |||
| Yes | 0 (0) | 30 (2) | .462 |
| No | 28 (100) | 1549 (98) | |
| White cell count | |||
| Median, ×109/L | 3.9 | 12.4 | |
| Less than 10 × 109/L, no. (%) | 19 (68) | 709 (44) | .013 |
| More than 10 × 109/L, no. (%) | 9 (32) | 893 (56) | |
| Immunophenotype, no. (%) | |||
| Early pre-B ALL | 0 (0) | 22 (1) | .210 |
| Common/pre-B ALL | 28 (100) | 1358 (86) | |
| T-cell ALL | 0 (0) | 184 (12) | |
| Other | 0 (0) | 14 (1) | |
| FAB type, no. (%) | |||
| L1 | 27 (100) | 1319 (94) | .201 |
| L2 | 0 (0) | 80 (6) | |
| CNS disease, no. (%) | |||
| Yes | 0 (0) | 31 (2) | .457 |
| No | 28 (100) | 1571 (98) | |
| BM blasts, no. (%) | |||
| Less than 90% | 5 (19) | 318 (22) | .742 |
| 90%-94% | 6 (23) | 294 (20) | |
| 95%-99% | 14 (54) | 688 (48) | |
| 100% | 1 (4) | 137 (10) | |
| Enlarged spleen, no. (%) | |||
| Yes | 8 (71) | 475 (30) | .871 |
| No | 20 (29) | 1109 (70) | |
| Enlarged liver, no. (%) | |||
| Yes | 6 (21) | 447 (28) | .427 |
| No | 22 (79) | 1136 (72) | |
| Anterior mediastinal mass, no. (%) | |||
| Yes | 1 (4) | 115 (7) | .447 |
| No | 27 (96) | 1452 (93) | |
| Hemogloblin, no. (%) | |||
| Less than 70 g/L | 11 (39) | 766 (48) | .341 |
| 70 g/L or more | 17 (61) | 818 (52) | |
| Platelets | |||
| Median, ×109/L | 22 | 44 | |
| Less than 25 × 109/L, no. (%) | 15 (54) | 501 (32) | .011 |
| 25-49 × 109/L, no. (%) | 8 (29) | 343 (22) | |
| 50-99 × 109/L, no. (%) | 0 (0) | 326 (21) | |
| 100 × 109/L or more, no. (%) | 5 (18) | 414 (26) | |
| Complete remission, no. (%) | |||
| Yes | 27 (96) | 1588 (99) | .138 |
| No | 1 (4) | 14 (1) | |
| Relapse, no. (%) | |||
| Yes | 17 (60) | 287 (18) | < .001 |
| No | 11 (39) | 1315 (82) | |
| Site of relapse, no. (%) | |||
| BM | 12 (71) | 213 (74) | .740 |
| CNS | 6 (35) | 93 (32) | .805 |
| Other | 0 (0) | 35 (12) | .126 |
| Dead, no. (%) | |||
| Yes | 9 (32) | 218 (14) | .005 |
| No | 19 (68) | 1384 (86) | |
| Cumulative incidence of relapse, % (range) | |||
| 3 y | 43 (27-63) | 15 (14-17) | |
| 5 y | 71 (52-87) | 22 (20-24) | |
| Event-free survival (5 y), % (range)† | 29 (13-48) | 78 (76-80) | |
| Observed-expected ratio‡ | 3.53 | 0.97 | < .001 |
| Overall survival (5 y), % (range)† | 71 (51-84) | 87 (85-88) | |
| Observed-expected ratio‡ | 2.54 | 0.98 | .004 |
| Variable* . | Patients with iAMP21 . | Patients without iAMP21 . | P . |
|---|---|---|---|
| Total, no. (%) | 28 (100) | 1602 (100) | |
| Sex, no. (%) | |||
| Female | 13 (46) | 693 (43) | .737 |
| Male | 15 (54) | 909 (57) | |
| Age, no. (%) | |||
| 1-4 y | 0 (0) | 812 (51) | < .001 |
| 5-9 y | 17 (61) | 458 (29) | |
| 10+ y | 11 (39) | 332 (21) | |
| Ethnicity, no. (%) | |||
| White | 1378 (87) | 23 (85) | .720 |
| Nonwhite | 197 (13) | 4 (15) | |
| Down syndrome, no. (%) | |||
| Yes | 0 (0) | 30 (2) | .462 |
| No | 28 (100) | 1549 (98) | |
| White cell count | |||
| Median, ×109/L | 3.9 | 12.4 | |
| Less than 10 × 109/L, no. (%) | 19 (68) | 709 (44) | .013 |
| More than 10 × 109/L, no. (%) | 9 (32) | 893 (56) | |
| Immunophenotype, no. (%) | |||
| Early pre-B ALL | 0 (0) | 22 (1) | .210 |
| Common/pre-B ALL | 28 (100) | 1358 (86) | |
| T-cell ALL | 0 (0) | 184 (12) | |
| Other | 0 (0) | 14 (1) | |
| FAB type, no. (%) | |||
| L1 | 27 (100) | 1319 (94) | .201 |
| L2 | 0 (0) | 80 (6) | |
| CNS disease, no. (%) | |||
| Yes | 0 (0) | 31 (2) | .457 |
| No | 28 (100) | 1571 (98) | |
| BM blasts, no. (%) | |||
| Less than 90% | 5 (19) | 318 (22) | .742 |
| 90%-94% | 6 (23) | 294 (20) | |
| 95%-99% | 14 (54) | 688 (48) | |
| 100% | 1 (4) | 137 (10) | |
| Enlarged spleen, no. (%) | |||
| Yes | 8 (71) | 475 (30) | .871 |
| No | 20 (29) | 1109 (70) | |
| Enlarged liver, no. (%) | |||
| Yes | 6 (21) | 447 (28) | .427 |
| No | 22 (79) | 1136 (72) | |
| Anterior mediastinal mass, no. (%) | |||
| Yes | 1 (4) | 115 (7) | .447 |
| No | 27 (96) | 1452 (93) | |
| Hemogloblin, no. (%) | |||
| Less than 70 g/L | 11 (39) | 766 (48) | .341 |
| 70 g/L or more | 17 (61) | 818 (52) | |
| Platelets | |||
| Median, ×109/L | 22 | 44 | |
| Less than 25 × 109/L, no. (%) | 15 (54) | 501 (32) | .011 |
| 25-49 × 109/L, no. (%) | 8 (29) | 343 (22) | |
| 50-99 × 109/L, no. (%) | 0 (0) | 326 (21) | |
| 100 × 109/L or more, no. (%) | 5 (18) | 414 (26) | |
| Complete remission, no. (%) | |||
| Yes | 27 (96) | 1588 (99) | .138 |
| No | 1 (4) | 14 (1) | |
| Relapse, no. (%) | |||
| Yes | 17 (60) | 287 (18) | < .001 |
| No | 11 (39) | 1315 (82) | |
| Site of relapse, no. (%) | |||
| BM | 12 (71) | 213 (74) | .740 |
| CNS | 6 (35) | 93 (32) | .805 |
| Other | 0 (0) | 35 (12) | .126 |
| Dead, no. (%) | |||
| Yes | 9 (32) | 218 (14) | .005 |
| No | 19 (68) | 1384 (86) | |
| Cumulative incidence of relapse, % (range) | |||
| 3 y | 43 (27-63) | 15 (14-17) | |
| 5 y | 71 (52-87) | 22 (20-24) | |
| Event-free survival (5 y), % (range)† | 29 (13-48) | 78 (76-80) | |
| Observed-expected ratio‡ | 3.53 | 0.97 | < .001 |
| Overall survival (5 y), % (range)† | 71 (51-84) | 87 (85-88) | |
| Observed-expected ratio‡ | 2.54 | 0.98 | .004 |
Median age for iAMP21 patients was 9 years; for other patients, it was 5 years.
Data were missing for some variables: ethnicity (n = 28), Down status (n = 23), immunophenotype (n = 24), FAB type (n = 204), BM blasts (n = 167), enlarged spleen (n = 18), enlarged liver (n = 19), anterior mediastinal mass (n = 35), and hemoglobin (n = 18).
The percentage of patients surviving event-free and overall is given plus the 95% CIs.
The observed-expected ratio was calculated from the log-rank test.